Limits...
To estimate the efficacy of 0.1% tacrolimus with Colgate Oraguard-B paste for the treatment of patients with symptomatic oral lichen planus.

Nisa SU, Saggu TK - Indian J Dent (2016 Jan-Mar)

Bottom Line: Sixty-five (43.33%) patients had marked resolution of their lesions, i.e., the size of the lesion was decreased.Fourteen (9.33%) patients had remission of lesion (reduction in burning sensation and size of lesion) in symptoms as recorded by the VAS.Topical tacrolimus ointment 0.1% in Oraguard-B paste is an effective treatment for different types of OLP.

View Article: PubMed Central - PubMed

Affiliation: Department of Oral Medicine and Radiology, Bharati Vidyapeeth Dental College and Hospital, Pune, Maharashtra, India.

ABSTRACT

Aim and objectives: To investigate the efficacy of 0.1% tacrolimus with Colgate Oraguard-B paste for the treatment of patients with oral lichen planus (OLP).

Materials and methods: One hundred and fifty patients with symptomatic OLP participated in the study, who had clinically and histopathologically proven OLP. In this study, patients were provided with 0.1% tacrolimus ointment with Colgate Oraguard-B paste as the study medication. Patients were asked to use the medication over the areas three times a day until resolution of the lesion. Patients were recalled to assess the drug response every 15 days. The duration of treatment ranged from 3 months to 4 months, with follow-up of 2 years and 6 months.

Statistical analysis: The Wilcoxon signed-rank test was performed, which is a nonparametric statistical hypothesis test for comparing two related samples, matched samples or repeated measurements on a single sample to assess whether their population mean ranks differ (i.e., it is a paired difference test). In our study, the pre- and post-Visual Analogue Scale (VAS) values were compared and the mean, standard deviation and P values were calculated.

Results: Of 150 patients, 71 (47.33%) patients had complete resolution of the lesion to the topical tacrolimus therapy. Sixty-five (43.33%) patients had marked resolution of their lesions, i.e., the size of the lesion was decreased. Fourteen (9.33%) patients had remission of lesion (reduction in burning sensation and size of lesion) in symptoms as recorded by the VAS.

Conclusion: Topical tacrolimus ointment 0.1% in Oraguard-B paste is an effective treatment for different types of OLP.

No MeSH data available.


Related in: MedlinePlus

Pre- and post-treatment response of tacrolimus therapy in different types of oral lichen planus
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4836094&req=5

Figure 2: Pre- and post-treatment response of tacrolimus therapy in different types of oral lichen planus

Mentions: The Wilcoxon signed-rank test was performed, which is a nonparametric statistical hypothesis test used when comparing two related samples, matched samples or repeated measurements on a single sample to assess whether their population mean ranks differ (i.e. it is a paired difference test). A total of 150 patients were enrolled in the study, of whom 43 patients had erosive OLP, 56 patients had reticular OLP, 34 patients had atrophic OLP and 17 patients had mixed lesions. All the patients had clinical evidence lesion followed by histopathological confirmation. The VAS was used to assess the improvement in pain intensity among different forms of lichen planus by recording the pre- and posttreatment values [Table 2 and Graph 1]. The demographic data were recorded along with type and site of lesion given in Table 1 and clinical scoring in Table 3.


To estimate the efficacy of 0.1% tacrolimus with Colgate Oraguard-B paste for the treatment of patients with symptomatic oral lichen planus.

Nisa SU, Saggu TK - Indian J Dent (2016 Jan-Mar)

Pre- and post-treatment response of tacrolimus therapy in different types of oral lichen planus
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4836094&req=5

Figure 2: Pre- and post-treatment response of tacrolimus therapy in different types of oral lichen planus
Mentions: The Wilcoxon signed-rank test was performed, which is a nonparametric statistical hypothesis test used when comparing two related samples, matched samples or repeated measurements on a single sample to assess whether their population mean ranks differ (i.e. it is a paired difference test). A total of 150 patients were enrolled in the study, of whom 43 patients had erosive OLP, 56 patients had reticular OLP, 34 patients had atrophic OLP and 17 patients had mixed lesions. All the patients had clinical evidence lesion followed by histopathological confirmation. The VAS was used to assess the improvement in pain intensity among different forms of lichen planus by recording the pre- and posttreatment values [Table 2 and Graph 1]. The demographic data were recorded along with type and site of lesion given in Table 1 and clinical scoring in Table 3.

Bottom Line: Sixty-five (43.33%) patients had marked resolution of their lesions, i.e., the size of the lesion was decreased.Fourteen (9.33%) patients had remission of lesion (reduction in burning sensation and size of lesion) in symptoms as recorded by the VAS.Topical tacrolimus ointment 0.1% in Oraguard-B paste is an effective treatment for different types of OLP.

View Article: PubMed Central - PubMed

Affiliation: Department of Oral Medicine and Radiology, Bharati Vidyapeeth Dental College and Hospital, Pune, Maharashtra, India.

ABSTRACT

Aim and objectives: To investigate the efficacy of 0.1% tacrolimus with Colgate Oraguard-B paste for the treatment of patients with oral lichen planus (OLP).

Materials and methods: One hundred and fifty patients with symptomatic OLP participated in the study, who had clinically and histopathologically proven OLP. In this study, patients were provided with 0.1% tacrolimus ointment with Colgate Oraguard-B paste as the study medication. Patients were asked to use the medication over the areas three times a day until resolution of the lesion. Patients were recalled to assess the drug response every 15 days. The duration of treatment ranged from 3 months to 4 months, with follow-up of 2 years and 6 months.

Statistical analysis: The Wilcoxon signed-rank test was performed, which is a nonparametric statistical hypothesis test for comparing two related samples, matched samples or repeated measurements on a single sample to assess whether their population mean ranks differ (i.e., it is a paired difference test). In our study, the pre- and post-Visual Analogue Scale (VAS) values were compared and the mean, standard deviation and P values were calculated.

Results: Of 150 patients, 71 (47.33%) patients had complete resolution of the lesion to the topical tacrolimus therapy. Sixty-five (43.33%) patients had marked resolution of their lesions, i.e., the size of the lesion was decreased. Fourteen (9.33%) patients had remission of lesion (reduction in burning sensation and size of lesion) in symptoms as recorded by the VAS.

Conclusion: Topical tacrolimus ointment 0.1% in Oraguard-B paste is an effective treatment for different types of OLP.

No MeSH data available.


Related in: MedlinePlus